Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gastrointestinal 1Breast 1

Conditions

Mesothelioma 1Lung Neoplasms 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Breast Neoplasms 1

Interventions

Oxaliplatin 10Capecitabine 9Cisplatin 8Fluorouracil 5Leucovorin 4Bevacizumab 4tegafur-gimeracil-oteracil 3pemigatinib 3atezolizumab 3Nivolumab 3trebananib 2ponatinib 2pembrolizumab 2avelumab 2apatinib 2alectinib 2XELOX 2Standard of Care 2S 1 (combination) 2Radiotherapy 2Radiosurgery 2Ocoxin 2Irinotecan 2Ipilimumab 2Gemcitabine 2Folfox protocol 2Everolimus 2Erlotinib Hydrochloride 2Acupuncture Therapy 2zanidatamab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Gastrointestinal Neoplasms × Plicamycin × Clear all
NCT01624090 2019-12-30

Mithramycin for Lung, Esophagus, and Other Chest Cancers

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
16 enrolled 13 charts
BreastGastrointestinalOther solid neoplasmThoracic

Breast Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Lung Neoplasms, Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡